drugset / Trial / NCT04364789
Phase I, First-In-Human Study of TT-00920 in Healthy Subjects
RandomizedSequentialDouble-blindTreatment
Summary
This is a first-in-human, randomized, double-blind, placebo-controlled study. The primary objectives of the study were to investigate the safety and tolerability and determine the PK profiles of single ascending doses (SAD) of TT-00920 administered to healthy subjects. The secondary objectives of the study were to assess the effect of food on the PK of TT-00920 following an oral dose.
Timeline
- Start
- 2020-02-05
- Primary completion
- 2021-06-18
- Completion
- 2022-03-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | TT-00920 | Unknown | 20 mg | Oral |
Indications
No indication recorded.